NASDAQ:GERN - Geron Stock Price, Forecast & News

Geron trades on the NASDAQ under the ticker symbol "GERN."

Geron Co. (NASDAQ:GERN) issued its quarterly earnings data on Wednesday, November, 6th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.14) by $0.06. The biopharmaceutical company earned $0.13 million during the quarter, compared to the consensus estimate of $0.10 million. Geron had a negative net margin of 7,044.88% and a negative return on equity of 29.22%. During the same quarter last year, the company earned $0.24 earnings per share. View Geron's Earnings History.

Geron is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Geron.

4 brokerages have issued twelve-month price objectives for Geron's shares. Their forecasts range from $3.00 to $4.00. On average, they expect Geron's stock price to reach $3.75 in the next twelve months. This suggests a possible upside of 247.2% from the stock's current price. View Analyst Price Targets for Geron.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Geron.

Media stories about GERN stock have trended very negative on Friday, according to InfoTrie Sentiment. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Geron earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Geron.

Some companies that are related to Geron include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Biogen (BIIB), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Geron investors own include Novavax (NVAX), TransEnterix (TRXC), Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), Anavex Life Sciences (AVXL), Puma Biotechnology (PBYI), Amarin (AMRN), Dynavax Technologies (DVAX), Bristol-Myers Squibb (BMY) and Horizon Therapeutics (HZNP).

Geron's stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Street Corp (1.82%), Geode Capital Management LLC (1.24%), Charles Schwab Investment Management Inc. (0.60%), Bank of America Corp DE (0.57%), Bank of New York Mellon Corp (0.41%) and Goldman Sachs Group Inc. (0.18%). Company insiders that own Geron stock include Elizabeth G O'farrell, Melissa Kelly Behrs, Robert J Spiegel and Stephen Rosenfield. View Institutional Ownership Trends for Geron.

GERN stock was sold by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, New York State Common Retirement Fund, Credit Suisse AG and UBS Asset Management Americas Inc.. View Insider Buying and Selling for Geron.

GERN stock was bought by a variety of institutional investors in the last quarter, including Bank of America Corp DE, California Public Employees Retirement System, Cambridge Investment Research Advisors Inc., Alpine Global Management LLC, Goldman Sachs Group Inc., State Street Corp, UBS Group AG and Geode Capital Management LLC. View Insider Buying and Selling for Geron.

Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GERN stock can currently be purchased for approximately $1.08.

Geron has a market capitalization of $215.76 million and generates $1.07 million in revenue each year. The biopharmaceutical company earns $-27,020,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. Geron employs 17 workers across the globe.View Additional Information About Geron.

The official website for Geron is http://www.geron.com/.

Geron's mailing address is 149 COMMONWEALTH DRIVE SUITE 2070, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected]